Diarrhoea is defined as the passage of three or more loose or liquid stools per day, representing a significant cause of morbidity and mortality, particularly among young children in Nigeria. The primary physiological disturbance involves an imbalance between intestinal absorption and secretion, leading to accelerated transit time. Pharmacological management aims to reduce stool frequency, prevent dehydration, and correct electrolyte imbalances, rather than merely suppressing symptoms.
Anti-diarrhoeal medications are categorized based on their pharmacological action to target different underlying mechanisms of loose stools:
Opioid derivatives such as loperamide and diphenoxylate are the most common motility inhibitors. They bind to opioid receptors in the intestinal wall, inhibiting acetylcholine release and decreasing propulsive peristalsis. While effective for acute non-invasive diarrhoea, these agents are strictly contraindicated in infectious dysentery or invasive bacterial diarrhoea. Slowing gut motility in the presence of invasive pathogens traps toxins and bacteria, potentially worsening systemic infection or causing toxic megacolon.
Agents like kaolin, pectin, and activated charcoal fall into this category. They act by adhering fluids, bacteria, and toxins to their particle surfaces, reducing stool water content and firming up consistency. A major clinical drawback of these agents is their non-specific binding capacity; they can interfere with the oral absorption of concurrently administered essential drugs, including antibiotics and cardiac glycosides. Patients must stagger drug administration times accordingly.
Racecadotril is an enkephalinase inhibitor that acts as an antisecretory drug, reducing hypersecretion of water and electrolytes into the intestinal lumen without affecting gut motility. It does not cause secondary constipation or toxic megacolon. Meanwhile, antimicrobial therapy is reserved for specific confirmed pathogens such as *Vibrio cholerae* or *Shigella* species, as routine use for viral or self-limiting acute diarrhoea promotes antimicrobial resistance.
Oral Rehydration Salt (ORS) solution remains the cornerstone of diarrhoea management, focusing on the sodium-glucose cotransport mechanism in the small intestine. Glucose enhances the active absorption of sodium, which in turn drives passive water absorption across the mucosal membrane. Zinc supplementation is co-administered with ORS in children under five for ten to fourteen days to reduce the duration and severity of the episode and prevent future occurrences.
Nurses must conduct thorough baseline and ongoing assessments of hydration status, skin turgor, mucous membrane moisture, and vital signs. Intake and output charts must be meticulously maintained, weighing all wet diapers or measuring liquid stool volumes where possible. Early identification of severe dehydration signs—such as sunken fontanelles, lethargy, or delayed capillary refill—ensures prompt escalation to intravenous fluid resuscitation.
Effective prevention centers on interrupting the fecal-oral transmission cycle through public health measures. Nurses must educate patients and caregivers on proper hand hygiene with soap and water, safe drinking water preparation, and hygienic food handling practices. Exclusive breastfeeding during the first six months of life and adherence to rotavirus immunization schedules offer powerful protection against severe childhood diarrhoeal diseases.